FDA approves new drug to treat Parkinson's

By
May 18, 2006 03:06

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Parkinson's patients on Wednesday gained a newly approved drug to help block the breakdown of a chemical that contributes to problems with movement and coordination that mark the progressive disease. The Food and Drug Administration said it approved Azilect, also called rasagiline, made by Teva Pharmaceutical Industries of Israel, for use as an initial single-drug therapy for early Parkinson's disease, and as an addition to levodopa in more advanced patients. Levodopa is a standard treatment for Parkinson's. "Parkinson's is a relentless disease with limited treatment options, and each new therapy is an important addition to the physicians' treatment options," said Dr. Steven Galson, director of the FDA's Center for Drug Evaluation and Research. Azilect is intended to help block the breakdown of dopamine, an important chemical for the cellular signaling that controls muscle movement.

Related Content

NOT FOR much longer. A man protests against Brexit in London.
August 17, 2018
London mayor Khan consults disaster planners over no-deal Brexit

By REUTERS